Although estrogens are known to control lipoprotein synthesis, the underlying mechanism remains elusive. A recent study by Della Torre et al.
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Although estrogens are known to control lipoprotein synthesis, the underlying mechanism remains elusive. A recent study by Della Torre et al. [1] explored a role for hepatic estrogen receptor a (ERa) in balancing lipid and cholesterol metabolism, a process affected by cycling estrogen levels. Uncoupling liver ERa may cause hepatic and cardiovascular disorders.
The investigators generated a liver-specific ERa knockout mouse model (LERKO) without disturbing the reproductive cycle. They used this model as an intermediator to elucidate the mechanistic relationship between ERa and cycling estrogen in the liver with liver X receptor a (LXRa), a transcriptional modulator of lipid and carbohydrate metabolism affected by the estrous cycle. ERa deficiency increased vacuole degeneration, lipid droplet size, collagen deposition, and expression of inflammatory genes. Syngenic (SYN) mice showed ERa fluctuation at different phases of the estrous cycle, along with oscillations in cholesterol metabolism. Researchers noted no analogous changes in LERKO mice. However, the LERKO mice accumulated triglycerides during the metestrus phase, whereas free fatty acids decreased during estrus. SYN mice showed little or no fluctuation in these particular lipids, highlighting a potential regulatory role for ERa in maintaining liver lipid homeostasis.
Using fast protein liquid chromatography, the authors observed similarities in lipoprotein profiles at each stage of the estrous cycle except proestrus: delayed elution of the highdensity lipoprotein (HDL) peak only occurred in SYN mice, indicating ERa involvement during this phase with a distinct class of HDLs. SYN mice also showed estrous-cycledependent changes in remodeling enzymes, phospholipid transfer protein, and hepatic lipase. Della Torre et al. [1] observed no such changes in LERKO mice, indicating a difference between these proestrus-generated HDLs and those generated in other phases, with a distinct tie to ERa for the latter's production.
The investigators then measured HDL cholesterol metabolism efflux capacity to determine the efficiency of reverse cholesterol metabolism transport, an important process in regulating HDL functionality. The SYN mice showed changing transport efficiency tuned to the estrous cycle, but LERKO mice lacked such fluctuations, resulting in reduced transport capacity. The resulting conclusion directly correlates ovarian hormonal output with liver metabolism.
Cotransfection of LXRa with ERa reduced LXRa transcriptional efficiency in the presence of estrogen due to competition between ERa and LXRa for common coregulators. The investigators found that ERa and LXRa binding was highest at proestrus, leading to increased transcription of LXRa genes. Lower estrogen levels decreased ERa interaction with LXRa. Such a coordinated association could contribute to the regulation of cycle-dependent hepatic lipid metabolism.
This relationship is important for women's health when considering the risk of nonalcoholic fatty liver disease. Cycling estrogen levels influence hepatic ERa, reshaping HDL particle size and regulating cholesterol transport. During their reproductive years, women are less prone to cholesterol diseases because of this interaction, with a marked increase of diagnosis postmenopause. Thus, to maintain healthy hepatic metabolic homeostasis and cardiovascular function, ERa is an important target for hormone replacement therapies.
